Search tips
Search criteria 


Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Clin Pathol. 1995 July; 48(7): 611–615.
PMCID: PMC502709

Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p.


AIMS--To determine if allelic loss on chromosomes 16q and 17p, commonly encountered in in situ and invasive ductal carcinomas, is present in atypical ductal hyperplasia (ADH); to determine whether ADH is a neoplastic (clonal) or hyperplastic (polyclonal) proliferation. METHODS--Fourteen cases of ADH were examined for allele loss at loci on chromosome 16q and 17p using a microdissection technique, polymorphic DNA markers and the polymerase chain reaction (PCR). RESULTS--Loss of heterozygosity (LOH) was detected in five of nine informative cases on chromosome 16q at the microsatellite D16S413 and two of eight informative cases on chromosome 17p at D17S796. CONCLUSIONS--The incidence of LOH at these loci is similar to that previously observed in ductal carcinoma in situ and in invasive ductal carcinoma. Because of the nature of the technique used, our findings also demonstrate that ADH is a monoclonal, and hence, neoplastic proliferation rather than a hyperplastic (polyclonal) condition as its name suggests. There is thus a case for including ADH, as presently defined, within the spectrum of ductal carcinoma in situ.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rosen PP. The pathological classification of human mammary carcinoma: past, present and future. Ann Clin Lab Sci. 1979 Mar-Apr;9(2):144–156. [PubMed]
  • Baker LH. Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin. 1982 Jul-Aug;32(4):194–225. [PubMed]
  • Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. [PubMed]
  • Sloane JP, Ellman R, Anderson TJ, Brown CL, Coyne J, Dallimore NS, Davies JD, Eakins D, Ellis IO, Elston CW, et al. Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology. Eur J Cancer. 1994;30A(10):1414–1419. [PubMed]
  • Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991 Mar;15(3):209–221. [PubMed]
  • Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol. 1992 Oct;23(10):1095–1097. [PubMed]
  • Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, Page DL. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992 Dec;16(12):1133–1143. [PubMed]
  • Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995 Feb;175(2):195–201. [PubMed]
  • Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer. 1990 Feb 1;65(3):518–529. [PubMed]
  • Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Børresen AL. Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosomes Cancer. 1992 Mar;4(2):113–121. [PubMed]
  • Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction. Cancer Res. 1994 Apr 1;54(7):1849–1853. [PubMed]
  • Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am. 1990 Aug;70(4):853–871. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group